Combined treatment with topical fluconazole microemulsion for Canine leishmaniasis: Case report

  • Carlos Bregni Department of Pharmaceutical Technology, Faculty of Pharmacy and Biochemistry, University of Buenos Aires. Buenos Aires
  • Claudia Salerno 1Department of Pharmaceutical Technology, Faculty of Pharmacy and Biochemistry, University of Buenos Aires. Buenos Aires
  • José Octavio Estévez Private Practice Veterinarian. Veterinaria del Oeste. Posadas, Misiones
  • María Cecilia Nevot Private Practice Veterinarian. Veterinaria del Oeste. Posadas, Misiones
  • Adriana M Carlucci Department of Pharmaceutical Technology, Faculty of Pharmacy and Biochemistry, University of Buenos Aires. Buenos Aires
  • Carlos Bregni Department of Pharmaceutical Technology, Faculty of Pharmacy and Biochemistry, University of Buenos Aires. Buenos Aires
Keywords: dogs, fluconazole, leishmaniasis, malassezia, microemulsion, zoonoses

Abstract

Canine leishmaniosis (CanL) is a zoonosis mainly caused by Leishmania infantum, (New World synonym L. chagasi) and occasionally by L. Braziliensis. CanL, also known as Canine Visceral Leishmaniosis, is a multisystemic disease with several clinical signs including poor body condition, generalized muscular atrophy, lymphadenomegaly and excessive skin ulcers and scaling. Fluconazole (FLZ) is an antifungal agent that inhibits a key enzyme for the production of ergosterol, the main sterol in membranes of fungi and parasites. We report a case of CanL in one dog with persistent cutaneous manifestations after early amelioration of systemic signs after usual treatment with allopurinol. A mongrel six-year-old female dog admitted in a veterinary clinic in the city of Posadas, Misiones, Argentina, was diagnosed with CanL after cytological examination of skin, lymph nodes and bone marrow, and treated with allopurinol as initial systemic treatment. Later a microemulsion with FLZ as active pharmaceutical ingredient was indicated for topical aplication on skin  lesions. The dog resolved lesions after combined treatment. This study provides baseline data about the efficacy of FLZ microemulsion on skin lesions of CanL. Although further work is needed, this semisolid dosage form could be useful for the local treatment of CanL in the New World.

Downloads

Download data is not yet available.

References

- Reithinger R, Dujardin JC, Louzir H, Pirmez C, Alexander B, Brooker S. Cutaneous Leishmaniasis. Lancet Infect Dis 2007; 7 (9) 581-596.

- Desjeux P. Leishmaniasis: current situation and new perspectives. Comp Immunol Microbiol Infect Dis 2004; 27 (5):305-18.´

- Salomon OD, Sinagra A, Nevot MC, Barberian G, Paulin P, Estevez JO, et al. First visceral leishmaniasis focus in Argentina. Mem Inst Oswaldo Cruz, Rio de Janeiro (2008). 103 (1): 109-111.

- Gómez N, Estevez O, Gisbert MA, Blanco A, Castillo V, Wolberg A. Leishmaniosis Visceral en los Caninos y Felinos: Actualización. Vet. Arg. 2011; 28: 282

- Solano-Gallego L, Koutinas A, Miro´ G, Cardoso L, Pennisi MG, Ferrer L, et al. Review. Directions for the diagnosis, clinical staging, treatment and prevention of canine leishmaniosis. Vet Parasitol 2009; 165: 1–18.

- Urbano J, Sanchez-Moreno ME, Ovalle CE, Rosales MJ, Camargo YC, Gutierrez-Sanchez R, et al. Characterization of cutaneous isolates of Leishmania in Colombia by isoenzyme typing and kDNA restriction analysis. Rev Ibero-Latinoam Parasitol 2011; 70 (1): 16-24.

- Cavalcanti A, Lobo R, Cupolillo E, Bustamante F, Porrozzi R. Canine cutaneous leishmaniasis caused by neotropical Leishmania infantum despite of systemic disease: A case report. Parasitol Int 2012. doi:10.1016/j.parint.2012.05.002

- Baneth G, Koutinas AF, Solano-Gallego L, Bourdeau P, Ferrer L. Review Canine leishmaniosis – new concepts and insights on an expanding zoonosis: part one. Trends Parasitol 2008; 24 (7) 324-330. doi:10.1016/j.pt.2008.04.001

- Miro´ G, Cardoso L, Pennisi MG, Oliva G, Baneth G. Review Canine leishmaniosis – new concepts and insights on an expanding zoonosis: part two. Trends Parasitol 2008; 24 (8) 371-377.

- Solano-Gallego L, Miró G, Koutinas A, Cardozo L, Pennisi MG, Ferrer L, et al. LeishVet guidelines for the practical management of canine leishmaniosis. Parasite Vector 2011; 4:86.

- Wildfeuer A, Faergemann J, Laufen H, Pfaff G, Zimmermann T, Seidl HP, et al. Bioavailability of fluconazole in the skin after oral medication. Mycoses 1994; 37 (3-4):127-130.

- Faergemann J. Pharmacokinetics of fluconazole in skin and nails. J Am Acad Dermatol 1999; 40 (6 Pt 2):S14-20.

- Laffitte E, Genton B, Panizzon RG. Cutaneous leishmaniasis caused by Leishmania tropica: treatment with oral fluconazole. Dermatology 2005; 210:249–251.

- Baron S, Laube S, Raafat F, Moss C. Cutaneous leishmaniasis in a Kosovan child treated with oral fluconazole. Clin Exp Dermatol 2004; 29:546–547.

- Alrajhi AA, Ibrahim EA, De Vol EB, Khairat M, Faris RM, Maguire JH. Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major. N Engl J Med 2002; 346:891–895.

- Sharp NJH, Harvey CE, O'Brien JA. Treatment of canine nasal aspergillosis/ penicilliosis with fluconazole. J Small Anim Pract 1991; 32 (10) 513–516,

- Tiches D, Vite CH, Dayrell-Hart B, Steinberg SA, Gross S, Lexa FA. A case of canine central nervous system cryptococcosis: management with fluconazole. J Am Anim Hosp Assoc 1998; 34 (2) 145-151.

- Salerno C, Carlucci A. M., Bregni C. Study of in vitro drug release and percutaneous absorption of fluconazole from topical dosage forms. AAPSPharmSciTech 2010;11( 2): 986-993.

-Salerno C, Carlucci AM, Gorzalczany S, Bregni C. In vitro Inhibition of Leishmania braziliensis Promastigotes Growth by a Fluconazole Microemulsion. J Mol Pharm Org Process Res 2014; 2: 115. doi: 10.4172/2329-9053.1000115

- Ferrer L, Baneth G, Bourdeau P, Koutias A, Miró G, Pennisi M.G. et al. Response to the letter: Some remarks about the LeishVet directions for the treatment of canine leishmaniosis. Letter to the Editor. Vet Parasitol 2010; 169: 418–420

Published
2015-10-17
Issue
Vol 1 No 2 (2015): JABBR
Section
Case Reports

Copyright (c) 2015 Research Journal of Veterinary Medicine

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).